American Journal of Kidney Diseases
Volume 56, Issue 3 , Pages 447-457 , September 2010

Low Medication Adherence and Hypertension Control Among Adults With CKD: Data From the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study

Received 3 December 2009 ,Accepted 17 February 2010.

References 

  1. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J. 1999;138:211–219
  2. Klag MJ, Whelton P, Randall B, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–18
  3. Perneger T, Nieto J, Whelton P, Klag M, Comstock G, Szklo M. A prospective study of blood pressure and serum creatinine: results from the ‘Clue’ Study and the ARIC Study. JAMA. 1993;269:488–493
  4. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001;161:1207–1216
  5. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006;166:1884–1891
  6. Peralta CA, Hicks LS, Chertow GM, et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension. 2005;45:1119–1124
  7. Plantinga LC, Miller ER, Stevens LA, et al. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006. Hypertension. 2009;54:47–56
  8. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19:357–362
  9. Hyre AD, Krousel-Wood MA, Muntner P, Kawasaki L, DeSalvo KB. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens (Greenwich). 2007;9:179–186
  10. Krousel-Wood M, Hyre A, Muntner P, Morisky D. Methods to improve medication adherence in patients with hypertension: current status and future directions. Curr Opin Cardiol. 2005;20:296–300
  11. Kim MT, Han HR, Hill MN, Rose L, Roary M. Depression, substance use, adherence behaviors, and blood pressure in urban hypertensive black men. Ann Behav Med. 2003;26:24–31
  12. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 2007;21:311–316
  13. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348–354
  14. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497
  15. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794–811
  16. Kurella TM, Wadley V, Yaffe K, et al. Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis. 2008;52:227–234
  17. Martins D, Tareen N, Zadshir A, et al. The association of poverty with the prevalence of albuminuria: data from the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2006;47:965–971
  18. Bruce MA, Beech BM, Sims M, et al. Social environmental stressors, psychological factors, and kidney disease. J Investig Med. 2009;57:583–589
  19. Shoham DA, Vupputuri S, Kshirsagar AV. Chronic kidney disease and life course socioeconomic status: a review. Adv Chronic Kidney Dis. 2005;12:56–63
  20. Howard VJ, Cushman M, Pulley L, et al. The Reasons for Geographic and Racial Differences in Stroke Study: objectives and design. Neuroepidemiology. 2005;25:135–143
  21. Morton LM, Cahill J, Hartge P. Reporting participation in epidemiologic studies: a survey of practice. Am J Epidemiol. 2006;163:197–203
  22. MESA Exam 1 Participation Rate. http://mesa-nhlbi.org/participation.aspxMESA Website [serial online] 2004. Accessed February 5, 2010
  23. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measurement. 1977;1:385–401
  24. Callahan CM, Unverzagt FW, Hui SL, Perkins AJ, Hendrie HC. Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care. 2002;40:771–781
  25. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74
  26. Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother. 2004;38:1363–1368
  27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  28. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612
  29. National Kidney Foundation KDOQI Work Group. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis. 2002;39(suppl 1):S46–S75
  30. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69–75
  31. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42:200–209
  32. Winkelmayer WC, Levin R, Setoguchi S. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin J Am Soc Nephrol. 2008;3:1415–1422
  33. Hong TB, Oddone EZ, Dudley TK, Bosworth HB. Medication barriers and anti-hypertensive medication adherence: the moderating role of locus of control. Psychol Health Med. 2006;11:20–28
  34. Ogedegbe G, Harrison M, Robbins L, Mancuso CA, Allegrante JP. Barriers and facilitators of medication adherence in hypertensive African Americans: a qualitative study. Ethn Dis. 2004;14:3–12
  35. Shea S, Misra D, Ehrlich MH, Field L, Francis CK. Correlates of nonadherence to hypertension treatment in an inner-city minority population. Am J Public Health. 1992;82:1607–1612
  36. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555–567
  37. Krousel-Wood M, Muntner P, Jannu A, Desalvo K, Re RN. Reliability of a medication adherence measure in an outpatient setting. Am J Med Sci. 2005;330:128–133
  38. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med. 2002;17:504–511
  39. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999;37:846–857
  40. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15:59–66
  41. Weiner DE, Tighiouart H, Levey AS, et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol. 2007;18:960–966
  42. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol. 2005;16:529–538

 Originally published online as doi:10.1053/j.ajkd.2010.02.348 on May 17, 2010.

PII: S0272-6386(10)00600-1

doi: 10.1053/j.ajkd.2010.02.348

American Journal of Kidney Diseases
Volume 56, Issue 3 , Pages 447-457 , September 2010

Article Tools

* Image Usage & Resolution